Abstract

Clinical pharmacology of cefuroxime and cefuroxime axetil in infants and children

Highlights

  • This non-toxic broad-spectrum cefuroxime is one of the few cephalosporins that may be administered parenterally and orally

  • Cefuroxime concentration in cerebrospinal fluid is about 10% of that in plasma and the drug successfully treated meningitis caused by β-haemolytic streptococci, Streptococcus pneumoniae, and Neisseria meningitides, but when Salmonella species are the infective pathogens additional 5 mg dose is given intraventricularly

  • The aim of this study is to review the published data on cefuroxime and cefuroxime axetil dosing, efficacy, safety, and cefuroxime effects, prophylaxis, treatment, optimization, meningitis, pharmacokinetics and bacterial-resistance

Read more

Summary

Introduction

This non-toxic broad-spectrum cefuroxime is one of the few cephalosporins that may be administered parenterally and orally. Cefuroxime is a β-lactamase resistant second-generation cephalosporin active against gram-positive organisms (including group B streptococci and penicillin-resistant staphylococci) and a wide range of gramnegative organisms. It is reasonable active against Haemophilus influenzae and Neisseria gonorrhoeae, but is inactive against Listeria, enterococci, Bacteroides, and Pseudomonas species. There are no published reports of the use of this formulation in children aged

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.